



Radiotherapeutics are driving up the nuclear medicine market

In the last few weeks two leading companies proved that radiotherapeutics are becoming the driving forces of the nuclear medicine market.

LOUVAIN-LA-NEUVE AND LALAYE, BELGIUM AND FRANCE, November 17, 2015

/EINPresswire.com/ -- In the last few weeks two leading companies proved that radiotherapeutics are becoming the driving forces of the nuclear medicine market.

Earlier this month, Bayer published once again strong results for its Xofigo (radium-223 dichloride), a product introduced on the US market in 2013 and used in the treatment of prostate and bone cancers, that is now reaching US\$ 210 million for the first nine months of 2015, growing by almost 50% from 2014.

Last week, Advanced Accelerator Applications S.A. (NASDAQ: AAAP) made its IPO at US\$16 and saw its stock surge to US\$ 25.02 (+56%) in just four days of trading. AAA is developing a radiotherapeutic, Lutathera (Lutetium-177 DOTATATE), intended for use in the treatment of patients with gastro-enteropancreatic neuroendocrine tumors (GEP-NET). Lutathera just completed its phase III clinical phase and is expected to be on the market by early 2017.

MEDraysintell recently showed in its report "Nuclear Medicine World Market Report and Directory" that new opportunities lie ahead in nuclear medicine, especially in the radiotherapeutic area with new products to reach the market before end of 2020. The global Nuclear Medicine market is expected to reach US\$ 24 billion in 2030, showing an annual average growth of 11%. The diagnostic radiopharmaceutical market is expected to grow, on average by 6% a year, mainly driven by volume but limited impact from new tracers, while the therapeutic radiopharmaceutical market is expected to grow 26% annually between 2014 and 2030.

To get more insights on these projections explore the Nuclear Medicine World Market Report & Directory, Edition 2015: a 930 pages report & directory describing and analyzing over 335 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in nuclear medicine. http://medraysintell.com/Nuclear_Medicine.html

About MEDraysintell

Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell was founded in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in nuclear medicine, proton therapy and radiotherapy. We aim to form an international team of experts in the field of medical radiation to provide strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the market – the competitive environment as well as the potential for mergers and acquisitions (M&A) – and technology development. MEDraysintell supports the decision process of manufacturers of radiopharmaceuticals and therapeutic radioisotopes, suppliers of equipment and software and members of the investor community. www.medraysintell.com

Paul-Emmanuel Goethals and Richard Zimmermann
MEDraysintell
+32 491 080 968 and +33 6 82 80 06 00
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.